These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 38087756)
41. Effects of enzyme replacement therapy on bone density in late onset Pompe disease. Avanti M; Martin A; Columbres RC; Mozaffar T; Kimonis V Mol Genet Metab; 2023 Nov; 140(3):107644. PubMed ID: 37515933 [TBL] [Abstract][Full Text] [Related]
42. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry. Scheidegger O; Leupold D; Sauter R; Findling O; Rösler KM; Hundsberger T J Neurol; 2018 Dec; 265(12):2783-2788. PubMed ID: 30232608 [TBL] [Abstract][Full Text] [Related]
43. Transcriptomic characterization of clinical skeletal muscle biopsy from late-onset Pompe patients. Kinton S; Dufault MR; Zhang M; George K Mol Genet Metab; 2023 Mar; 138(3):107526. PubMed ID: 36774918 [TBL] [Abstract][Full Text] [Related]
44. Enzyme replacement therapy for infantile-onset Pompe disease. Chen M; Zhang L; Quan S Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436 [TBL] [Abstract][Full Text] [Related]
45. The humanistic burden of Pompe disease: are there still unmet needs? A systematic review. Schoser B; Bilder DA; Dimmock D; Gupta D; James ES; Prasad S BMC Neurol; 2017 Nov; 17(1):202. PubMed ID: 29166883 [TBL] [Abstract][Full Text] [Related]
47. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031 [TBL] [Abstract][Full Text] [Related]
48. Advances in diagnosis and management of Pompe disease. Davison JE J Mother Child; 2020 Oct; 24(2):3-8. PubMed ID: 33554498 [TBL] [Abstract][Full Text] [Related]
49. Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study. Hahn SH; Kronn D; Leslie ND; Pena LDM; Tanpaiboon P; Gambello MJ; Gibson JB; Hillman R; Stockton DW; Day JW; Wang RY; An Haack K; Shafi R; Sparks S; Zhao Y; Wilson C; Kishnani PS; Genet Med; 2018 Oct; 20(10):1284-1294. PubMed ID: 29565424 [TBL] [Abstract][Full Text] [Related]
50. The new horizons for treatment of Late-Onset Pompe Disease (LOPD). Guémy C; Laforêt P Rev Neurol (Paris); 2023; 179(1-2):81-89. PubMed ID: 36609019 [TBL] [Abstract][Full Text] [Related]
51. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. Toscano A; Schoser B J Neurol; 2013 Apr; 260(4):951-9. PubMed ID: 22926164 [TBL] [Abstract][Full Text] [Related]
52. Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease. Moriggi M; Capitanio D; Torretta E; Barbacini P; Bragato C; Sartori P; Moggio M; Maggi L; Mora M; Gelfi C Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799647 [TBL] [Abstract][Full Text] [Related]
53. Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy. Parini R; De Lorenzo P; Dardis A; Burlina A; Cassio A; Cavarzere P; Concolino D; Della Casa R; Deodato F; Donati MA; Fiumara A; Gasperini S; Menni F; Pagliardini V; Sacchini M; Spada M; Taurisano R; Valsecchi MG; Di Rocco M; Bembi B Orphanet J Rare Dis; 2018 Feb; 13(1):32. PubMed ID: 29422078 [TBL] [Abstract][Full Text] [Related]
54. The impact of antibodies in late-onset Pompe disease: a case series and literature review. Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277 [TBL] [Abstract][Full Text] [Related]
55. Enzyme replacement therapy for infantile Pompe disease during the critical period and identification of a novel mutation. But WM; Lee SH; Chan AO; Lau GT Hong Kong Med J; 2009 Dec; 15(6):474-7. PubMed ID: 19966354 [TBL] [Abstract][Full Text] [Related]
56. Pompe disease: design, methodology, and early findings from the Pompe Registry. Byrne BJ; Kishnani PS; Case LE; Merlini L; Müller-Felber W; Prasad S; van der Ploeg A Mol Genet Metab; 2011 May; 103(1):1-11. PubMed ID: 21439876 [TBL] [Abstract][Full Text] [Related]